|

Our collaborator Mr Colin Hopper of University
College Hospital, London, with the EX1301 OCT Microscope.
Publications:

Optical Coherence Tomography Aids Cancer Detection
Full paper available
here
Exhibition news:

MICROSCIENCE 2008, ExCeL, London, 23 - 26 June 08
A UK opportunity to see Michelson Diagnostics’
ground-breaking EX1301 OCT Microscope, demonstrations can be booked in
advance by contacting
Dr Gordon McKenzie on +44 121 288 8530 or +44 7973 343414 (mobile)
Also featuring in the Micro Science workshop
program:
'Optical Coherence Tomography, imaging where
microscopes cannot reach'.
Led by
Jon Holmes, Thursday 26th June, 12.30
- 13.15, Area 1
|
Accelerating cancer care with
instant imaging
Michelson Diagnostics Ltd (MDL) is developing
an
imaging instrument for use during cancer diagnosis and treatment. This will, in many cases,
replace or improve the current method of taking tissue samples for offline laboratory
analysis. The device uses optical coherence tomography (OCT) to provide
real-time images of
sub-surface tissue at near-cellular resolution without tissue removal - an 'optical biopsy'.
Product
Michelson Diagnostics is proud to present its first
product, the EX1301 OCT Microscope (as pictured on the left). This
instrument brings turn-key OCT imaging to the research market,
providing ease of use and unparalleled resolution in a compact, reliable
package.
The unit is packaged with MDL's
intuitive 'Image 4' software, optimised to compliment the research user's
workflow by allowing access to both raw data and processed images, and
automatically storing experimental parameters and researcher's notes.
The EX1301 OCT microscope is
also available featuring a motorized stage with system controlled data
acquisition, enabling the user to capture 'slices' of data from their sample. These can be
processed to produce 3D-rendered images or 'fly-through' videos, or examined
slice-by-slice to help find the best match with histopathology.
MDL offers interested UK customers the option of a free,
fully-supported 2 day demonstration at the customer's premises. In addition,
a rental program is available for more in depth evaluation. For
more information please see here, or
for a brochure please click
here.
Technology
OCT is a platform technology, but
initial applications are:
-
Detection of tumour borders during surgery.
For example, in lung cancer the drive is the urgent need to reduce the 20% patient
death rate from recurrences of the disease post-surgery. 40-50,000 cancer surgery
theatres worldwide.
-
Barrett's Oesophagus, where OCT could remove the
current need for large numbers of biopsies to be taken blindly when cancer
is suspected. OCT could target the taking of conventional biopsies, or
could allow in-situ therapy to be applied accurately, saving costs and
relieving the burden on histopathology units.
Test program
MDL have two units in clinical testing with leading UK
NHS Trusts.
The first is at Gloucestershire Royal Hospital, being
used by Dr Nick Stone's Biophotonics Group to investigate clinical
pathologies including Cervical Cancer and Barrett's Oesophagus. Dr Stone's
group have
recently reported their first, very encouraging results, and have also
published in
Biophotonics International.
The second was with Mr. Colin Hopper's group at University College
Hospital, London, where they were examining Maxillofacial, Oral and Skin
cancer. They have also
reported
their first results, and a publication will follow in Oral Oncology
later this year.
Much more information will follow
shortly as our plans become public. In the meantime you can
contact us for more information.
|